HAYWARD, Calif.--(BUSINESS WIRE)--Oct. 24, 2017--
Pulse Biosciences, Inc., (Nasdaq: PLSE) a medical technology company
developing a proprietary therapeutic tissue treatment based on its
Nano-Pulse Stimulation (NPS) platform, today announced it will host its
quarterly investor conference call on Tuesday, November 7, 2017 at 1:30
p.m. PST / 4:30 p.m. EST.
Conference Call Details
Analysts and investors can participate in the conference call by dialing
(844) 494-0190 (U.S. toll-free) or (508) 637-5580 (international) using
Conference ID 1522560. Listeners will also be able to access the call
via webcast available on the Investor Section of the company’s website
at www.pulsebiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a medical technology company developing a
therapeutic tissue treatment platform based on Nano-Pulse Stimulation, a
proprietary cell signaling technology. Nano-Pulse Stimulation is a
non-thermal, precise, focal drug-free tissue treatment technology that
directly affects the cell membrane and intracellular structures to
stimulate unique behaviors in cells. NPS can initiate a cell death
process that allows for the treatment of tissue cells with minimal
inflammatory response which improves healing outcomes and supports the
replacement of treated tissue cells with healthy tissue cells. In
cancerous lesions, NPS has been shown in preclinical models to induce
immunogenic cell death (ICD), exposing the unique antigens of the
treated cells to the immune system. This process results in the
generation of cytotoxic T-cells and the mounting of an adaptive immune
response targeted against those cells. Pulse Biosciences is
investigating a variety of applications for its technology that exploits
the technology’s unique biologic effect, including immuno-oncology,
dermatology and veterinary medicine. More information is available at www.pulsebiosciences.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171024006674/en/
Source: Pulse Biosciences, Inc.
Investors:
Pulse Biosciences, Inc.
Brian Dow, SVP and Chief
Financial Officer
IR@pulsebiosciences.com
or
The
Trout Group
Mike Zanoni, 646-378-2924
mzanoni@troutgroup.com
or
Media:
Sam
Brown, Inc.
Christy Curran, 615-414-8668
christycurran@sambrown.com
